Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Center, San Raffaele Hospital Neuroendocrine Tumor Group (ENETS Center of Excellence), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy.
J Endocrinol Invest. 2022 Apr;45(4):705-718. doi: 10.1007/s40618-021-01705-2. Epub 2021 Nov 13.
Patients submitted to curative surgery for non-functioning pancreatic neuroendocrine neoplasms (NF-PanNENs) exhibit a variable risk of disease relapse. Aims of this meta-analysis were to estimate the rate of disease recurrence and to investigate the risk factors for disease relapse in patients submitted to curative surgery for NF-PanNENs.
Medline/Pubmed and Web of Science databases were searched for relevant studies. A meta-regression analysis was performed to investigate the source of recurrence rate heterogeneity. Pooled hazard ratios (HRs) and 95% confidence intervals (95% CI) were used to assess the effect of each possible prognostic factor on disease-free survival.
Fifteen studies, involving 2754 patients submitted to curative surgery for NF-PanNENs, were included. The pooled rate of disease recurrence was 21% (95% CI 15-26%). Study quality (Odds ratio, OR 0.94, P = 0.016) and G3-PanNENs rate (OR 2.18, P = 0.040) independently predicted the recurrence rate variability. Nodal metastases (HR 1.63, P < 0.001), tumor grade G2-G3 (G1 versus G2: HR 1.72, P < 0.001, G1 versus G3 HR 2.57, P < 0.001), microvascular (HR 1.25, P = 0.046) and perineural (HR 1.29, P = 0.019) invasion were identified as significant prognostic factors. T stage (T1-T2 versus T3-T4, P = 0.253) and status of resection margins (R0 versus R1, P = 0.173) did not show any significant relationship with NF-PanNENs recurrence.
Disease relapse occurs in approximately one out of five patients submitted to curative surgery for NF-PanNENs. Nodal involvement, tumor grade, microvascular and perineural invasion are relevant prognostic factors, that should be taken into account for follow-up and for possible trials investigating adjuvant or neoadjuvant treatments.
接受根治性手术治疗的无功能性胰腺神经内分泌肿瘤(NF-PanNENs)患者存在疾病复发的可变风险。本荟萃分析的目的是估计疾病复发率,并探讨接受 NF-PanNENs 根治性手术治疗的患者疾病复发的危险因素。
检索 Medline/Pubmed 和 Web of Science 数据库中相关研究。进行荟萃回归分析以研究复发率异质性的来源。使用合并风险比(HR)和 95%置信区间(95%CI)评估每个可能的预后因素对无病生存的影响。
纳入了 15 项研究,共涉及 2754 例接受 NF-PanNENs 根治性手术的患者。疾病复发率的汇总率为 21%(95%CI 15-26%)。研究质量(优势比,OR 0.94,P=0.016)和 G3-PanNENs 发生率(OR 2.18,P=0.040)独立预测了复发率的变异性。淋巴结转移(HR 1.63,P<0.001)、肿瘤分级 G2-G3(G1 与 G2:HR 1.72,P<0.001,G1 与 G3 HR 2.57,P<0.001)、微血管(HR 1.25,P=0.046)和神经周围(HR 1.29,P=0.019)侵犯被确定为显著的预后因素。T 分期(T1-T2 与 T3-T4,P=0.253)和切除边缘状态(R0 与 R1,P=0.173)与 NF-PanNENs 复发无显著关系。
大约五分之一接受 NF-PanNENs 根治性手术治疗的患者会出现疾病复发。淋巴结受累、肿瘤分级、微血管和神经周围侵犯是相关的预后因素,应在随访和可能的辅助或新辅助治疗试验中考虑这些因素。